Unicycive Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals

Los altos, calif., april 10, 2024 (globe newswire) -- unicycive therapeutics, inc. (nasdaq: uncy), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “company or “unicycive”), today announced that shalabh gupta, m.d., chief executive officer will present a company update at the noble capital markets emerging growth virtual healthcare equity conference on thursday april 18, 2024 at 11:00 a.m. et.

– oxylanthanum carbonate (olc) topline data expected in q2 2024 – – uni-494 granted orphan drug designation in delayed graft function of acute kidney injury – – uni-494 phase 1 single ascending dose portion of clinical trial complete – los altos, calif., march 28, 2024 (globe newswire) -- unicycive therapeutics, inc. (nasdaq: uncy) (the “company” or “unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the year ended december 31, 2023, and provided a business update.

Los altos, calif., march 25, 2024 (globe newswire) -- unicycive therapeutics, inc. (nasdaq: uncy), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “company or “unicycive”), today announced that multiple presentations will be delivered on the company's product candidates, oxylanthanum carbonate (olc) and uni-494, at the 61st european renal association (era) congress taking place may 23-26, 2024, in stockholm, sweden.

Led by new investors octagon capital and great point partners, llc, with participation from new and existing investors including logos capital, nantahala capital, silverarc capital, velan capital, vivo capital and walleye capital led by new investors octagon capital and great point partners, llc, with participation from new and existing investors including logos capital, nantahala capital, silverarc capital, velan capital, vivo capital and walleye capital

– promising preclinical results in delayed graft function of acute kidney injury – – uni-494 phase 1 single ascending dose portion of clinical trial complete – los altos, calif., march 13, 2024 (globe newswire) -- unicycive therapeutics, inc. (nasdaq: uncy), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “company or “unicycive”), today announced that two presentations related to uni-494 were presented on march 12, 2024 at the 29th international conference on advances in critical care nephrology aki and crrt 2024.

LOS ALTOS, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will present a company update at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on Thursday April 18, 2024 at 11:00 a.m. ET.

LOS ALTOS, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that two posters related to the Company's lead product candidate, oxylanthanum carbonate (OLC), will be presented at the National Kidney Foundation Spring Clinical Meeting taking place May 14-18, 2024, in Long Beach, California.

Unicycive (UNCY) rises after the encouraging progress in the late-stage development of its lead candidate, OLC, for the hyperphosphatemia indication. The NDA submission is expected around mid-2024.

LOS ALTOS, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in two upcoming investor conferences in December 2023.

Investing in undervalued penny stocks is always going to be about the same few things. Most investors are attempting to find cheap, short-term plays with reasonable catalysts in their favor.

Unicycive Therapeutics (NASDAQ: UNCY ) stock is falling on Friday after the medical company provided investors with an update from regulators. According to the clinical-stage biotechnology company, the FDA wants further information concerning lanthanum dioxycarbonate (LDC).

LOS ALTOS, Calif., June 16, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, announced today that Company CEO, Shalabh Gupta, MD, has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET 

Use these tips for analyzing penny stocks after a market crash The post Analyzing Penny Stocks After a Market Crash, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Use these tips for identifying promising penny stocks The post How to Identify Promising Penny Stocks: 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Use these tips for future proofing your penny stocks strategy The post How to Future Proof Your Penny Stocks Investing Strategy  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.